IT shares surge most in a year, helping benchmarks end losing streak

IT shares surge most in a year, helping benchmarks end losing streak



Information technology (IT) shares recorded their biggest single-day advance in over a year on Tuesday amid growing confidence that AI adoption may complement, rather than disrupt, the sector.

 


The Nifty IT index ended at 31,117, gaining 4.2 per cent, their biggest single-day gain since May 12, 2025. The rally extended the Nifty IT index’s three-day gain to 7.6 per cent and also helped the benchmark Sensex and Nifty indices snap their four-day losing streak.

 


The recent IT rally was also supported by strong earnings from US-based cloud software firm Snowflake that lifted optimism around global software spending.

 


IT stocks, which had come under pressure in recent months amid concerns over AI-driven disruption to traditional outsourcing models, are now finding favour as investors bet that wider adoption of artificial intelligence could create fresh demand for software services.

 
 


The Sensex rose 383 points, or 0.5 per cent, to close at 74,650, while the Nifty50 gained 101 points, or 0.4 per cent, to end at 23,484. The market capitalisation of BSE-listed companies increased by nearly ₹2 trillion to ₹462.68 trillion.

 


Sentiment also received a boost after US President Donald Trump said talks with Iran were continuing. Earlier reports suggesting that Iran had suspended indirect negotiations had rattled investors. Brent crude fell 1.9 per cent to $93.36 a barrel. Apart from IT, consumer durable stocks were among the top gainers, with the Nifty Consumer Durables index advancing 1.3 per cent.

 


“Markets recovered from initial losses, led by gains in the IT sector, while continued accumulation in large-cap stocks reflected comfort with valuations, as the Nifty 50 trades closer to its long-term averages than the relatively richer valuations in broader markets. Despite ongoing delays in a Middle East truce, global sentiment remained stable, highlighting resilience in risk appetite,” said Vinod Nair, head of research at Geojit Investments.

 


With the earnings season largely behind, investor attention is expected to shift to macroeconomic triggers, including the progress of the monsoon and the outcome of the RBI’s monetary policy meeting.

 


“The monsoon is expected to advance into southern regions this week, providing near-term sentiment support. While rainfall is projected to be below the long-period average and emerging El Niño risks warrant monitoring, healthy reservoir levels—well above the 10-year average—offer a cushion against potential shortfalls,” Nair said.

 


Foreign portfolio investors (FPIs) sold shares worth ₹8,363 crore, while domestic investors injected ₹9,589 crore.  


Market breadth remained mixed, with 2,244 stocks advancing against 1,970 declines. Infosys, up 5.6 per cent, contributed the most to the Sensex’s gains, followed by TCS, which climbed 6.5 per cent. Meanwhile, NTPC (down 2.9 per cent), Axis Bank (-1.9 per cent) and Power Grid (down 1.4 per cent) were the biggest Sensex losers.

 


“While a weaker rupee provides some support to IT services and valuations in BFSI appear reasonable, we remain mindful of risks such as higher commodity prices and their potential impact on margins in certain growth-oriented sectors,” said Rahul Singh, CIO – Equities, Tata Asset Management.

 



Source link

Alkem launches semaglutide in ready-to-use single-shot pre-filled syringes

Alkem launches semaglutide in ready-to-use single-shot pre-filled syringes


Alkem Laboratories announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths at price starting Rs 350.

Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience.

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 02 2026 | 6:31 PM IST



Source link

Alkem launches semaglutide in ready-to-use single-shot pre-filled syringes

Board of Canara Bank approves capital raising up to Rs 8,500 cr for FY 2027


At meeting held on 02 June 2026

The board of Canara Bank in its meeting held today on 02 June 2026 has approved the Capital Raising Plan of the Bank for the financial year 2026-27 amounting upto Rs.8,500 crore by way of Debt Instruments (Additional Tier I/Tier II Bonds).

Further, out of the above Capital Raising Plan, the Board of Directors of the Bank has approved the following:

To raise Capital through Basel III Compliant Additional Tier I Bonds to the extent of Rs.4,500 crore during the FY 2026-27, subject to market conditions and necessary approvals.
To raise Capital through Basel III Compliant Tier II Bonds to the extent of Rs.4,000 crore during the FY 2026-27, subject to market conditions and necessary approvals.  

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 02 2026 | 6:31 PM IST



Source link

Alkem launches semaglutide in ready-to-use single-shot pre-filled syringes

Indian Overseas Bank receives IFSCA approval for branch at GIFT City


Indian Overseas Bank announced that the International Financial Services Centres Authority (IFSCA) vide its letter dated 01 Junbe 2026 has granted license to the Bank to set up an IFSC Banking Unit (IBU) i.e., as a Branch at GIFT City (GIFT IFSC), Gujarat.

The validity of the license is perpetual and subject to such terms and conditions as may be specified by IFSCA.

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 02 2026 | 6:31 PM IST



Source link

Alkem launches semaglutide in ready-to-use single-shot pre-filled syringes

Karnataka Bank partners with Tobacco Board


To provide customized financial solutions to registered tobacco growers across Karnataka

Karnataka Bank has entered into a strategic partnership with the Tobacco Board, Government of India, to provide customized financial solutions to registered tobacco growers across Karnataka on 29 May 2026.

Under this initiative, Karnataka Bank will offer a dedicated suite of banking and credit facilities designed specifically to meet the financial requirements of tobacco farmers registered with the Tobacco Board. The initiative aims to facilitate timely access to credit, promote financial inclusion, and support the sustainable growth of the tobacco farming community.

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 02 2026 | 6:31 PM IST



Source link

Alkem launches semaglutide in ready-to-use single-shot pre-filled syringes

Concord Biotech receives USFDA approval for Mycophenolate Mofetil for Oral Suspension USP


Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Mycophenolate
Mofetil for Oral Suspension USP, 200 mg/mL. Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Jun 02 2026 | 6:16 PM IST



Source link

YouTube
Instagram
WhatsApp